Does testosterone cause hair loss? Separating hormonal fact from fiction

Testosterone itself isn’t the direct cause of male pattern hair loss; the issue arises when 5‑alpha reductase converts it into DHT, which miniaturizes genetically androgen‑sensitive scalp follicles even when total testosterone is normal. With androgenetic alopecia affecting roughly 30% to 50% of men by age 50, the real question is whether your follicles are “wired” to overreact, and what that means for TRT and treatment options.

Key takeaways

• Testosterone does not directly cause male pattern hair loss. Risk depends mainly on how sensitive the scalp follicles are to androgens, which is genetic, not on having high circulating total testosterone.
• Hair loss is driven when 5-alpha reductase converts testosterone into dihydrotestosterone (DHT). DHT is several times more potent at androgen receptors and triggers follicle miniaturization by shortening the anagen growth phase.
• Androgenetic alopecia affects roughly 30% to 50% of men by age 50. It typically presents with temple recession, crown (vertex) thinning, or both, as hairs become progressively finer and shorter.
• TRT can accelerate hair loss in genetically susceptible men by increasing the testosterone available for DHT production. Diagnosis of hypogonadism is clinical and requires persistent symptoms plus consistently low morning testosterone on repeated tests, interpreted together with LH and FSH.
• Depending on history and exam, a clinician may order targeted labs to confirm hypogonadism or rule out common mimics of thinning hair, since androgenetic alopecia is usually a clinical diagnosis. Evidence-based treatment for androgenetic alopecia includes finasteride, a 5-alpha reductase inhibitor (Kaufman et al., Journal of the American Academy of Dermatology, 1998),^[1] and minoxidil. Expect about 3 to 6 months for shedding to slow and 6 to 12 months for visible regrowth.

The relationship

Testosterone does not directly cause male pattern hair loss. It is the raw material the body converts into dihydrotestosterone (DHT), and DHT acting on genetically sensitive scalp follicles drives the condition known as androgenetic alopecia. According to Kaufman and colleagues’ 1998 finasteride trial report in the Journal of the American Academy of Dermatology, androgenetic alopecia is caused by androgen-dependent miniaturization of scalp hair follicles, with scalp DHT implicated as a contributing cause.^[1]

Androgenetic alopecia is the most common form of hair loss in men. According to a 1998 community-based study by Rhodes and colleagues in Dermatologic Surgery, 42% of healthy men aged 18 to 49 had moderate to extensive hair loss, and the proportion rose with age, from 16% of men aged 18 to 29 to 53% of men aged 40 to 49.^[2] Men with androgenetic alopecia do not, as a group, have higher circulating total testosterone than men who keep their hair. The difference lies in an inherited sensitivity of scalp follicles to androgens (male hormones).

Hamilton’s 1951 paper in Annals of the New York Academy of Sciences sorted patterned hair loss in men into types and recorded how often each type appeared.^[3] That work underlies the Hamilton scale, later revised by Norwood, which clinicians still use to grade recession at the temples and thinning at the crown. Androgens are needed for the process to start: men castrated before puberty, who never produce adult levels of testosterone, do not develop pattern baldness.

How it works

Hair loss in androgenetic alopecia involves three steps: conversion of testosterone to DHT, binding of DHT to receptors in scalp follicles, and gradual shrinking of those follicles.

From testosterone to DHT

Testosterone circulates in the blood, but in some tissues it acts mainly after conversion. An enzyme called 5-alpha reductase (5-AR) converts testosterone into dihydrotestosterone (DHT), a more potent androgen.

DHT binds androgen receptors more strongly than testosterone does, and it is DHT, not testosterone itself, that drives the balding process in the scalp. In men with male pattern baldness, the balding areas of the scalp tend to have more 5-AR activity and more androgen receptors than the areas that keep their hair, while blood testosterone is usually normal.

Follicular miniaturization

When DHT binds to susceptible follicles, it shortens the growth phase (anagen) of the hair cycle, and over time the follicle shrinks. This is called miniaturization: each cycle produces a shorter, thinner hair until the follicle no longer makes a visible hair. According to Whiting’s 1993 biopsy study in the Journal of the American Academy of Dermatology, which compared 106 men with male pattern androgenetic alopecia with 22 controls, the diagnosis is confirmed by finding fewer terminal (full-thickness) hairs and more vellus hairs and stelae, the fibrous tracts left behind by shrunken follicles.^[4]

As the growth phase shortens, the resting phase (telogen) lengthens. The hair produced becomes fine and unpigmented (vellus hair) and eventually disappears. The loss typically follows a predictable pattern, receding from the temples and thinning at the crown (vertex), while sparing the hair on the back and sides of the head, which is genetically resistant to DHT.

The impact of exogenous testosterone

For men considering testosterone replacement therapy (TRT), whether treatment will cost them hair is a practical question. Exogenous testosterone increases the total amount of substrate available to the 5-AR enzyme.

In a man genetically prone to male pattern baldness, raising testosterone with TRT can speed up hair loss by supplying more testosterone for DHT production. In men without that sensitivity, keeping testosterone within the normal range does not typically trigger balding.

Clinicians diagnose low testosterone in context, not from a single number. According to the American Urological Association’s 2018 guideline, testosterone deficiency is diagnosed when symptoms are present and total testosterone is below 300 ng/dL on two early morning measurements taken on separate occasions; the guideline also recommends measuring luteinizing hormone (LH) in men with low testosterone.^[5] LH and follicle-stimulating hormone (FSH), measured alongside testosterone, separate a testicular (primary) cause from a pituitary or hypothalamic (secondary) one, and that distinction determines which treatments are suitable.

Conditions linked to it

The hormonal environment behind hair loss is also involved in other male health conditions. DHT circulates throughout the body, so its effects are not limited to the scalp.

Benign prostatic hyperplasia (BPH): The prostate is highly sensitive to DHT, and the same enzyme that drives hair loss also drives prostate enlargement. Some observational studies report an association between earlier-onset androgenetic alopecia and later BPH, although this does not prove causation. Finasteride at 5 mg daily is a treatment for BPH; the 1 mg dose used for hair loss is not prescribed for urinary symptoms.

Prostate cancer risk: Some epidemiological studies have examined whether vertex balding is linked to prostate cancer. The results have been inconsistent. Both conditions depend on androgens, but balding is not an established predictor of prostate cancer or of aggressive disease.

Metabolic syndrome: Some population studies have observed an association between early-onset male pattern baldness and markers of metabolic syndrome, including hypertension and insulin resistance. Proposed mechanisms include chronic inflammation and hormonal dysregulation, but findings vary by study design and population.

These associations come from population studies. They do not mean that a man with hair loss will develop prostate disease or heart disease. The conditions share some biology, but individual outcomes vary widely, so hair loss is a reason to keep up with routine screening rather than a diagnosis of anything else.

Symptoms and signals

Telling androgen-driven hair loss apart from other causes, such as stress or nutrient deficiency, guides treatment. Signs that DHT is the driver include:

• Patterned recession: The hairline recedes at the temples, creating an “M” shape. This is the hallmark of androgenetic alopecia.
• Vertex thinning: Hair density decreases at the crown. This may happen on its own or together with hairline recession.
• Change in texture: Before falling out, hairs in the affected areas often become finer, lighter, and shorter because of miniaturization.
• Absence of other symptoms: Unlike alopecia areata, an autoimmune condition that causes patchy spots, or telogen effluvium, a rapid, diffuse shedding triggered by stress or illness, androgenetic alopecia is usually gradual and does not involve itching, pain, or scarring.
• Family history: If your maternal or paternal grandfather, or your father, had significant hair loss, the likelihood that your hair loss is androgen-driven increases.

What to do about it

Androgenetic alopecia is progressive, and treatment works best while follicles remain. In Whiting’s biopsy study, among 44 men treated with topical minoxidil, the five with fewer than 2 follicular structures per square millimeter showed no regrowth, while 72% to 86% of men with higher follicle densities regrew hair.^[4]

1. Testing and verification: Before starting any treatment, establish a baseline with a clinician. Androgenetic alopecia is usually diagnosed clinically, and labs are targeted to rule out mimics or, if TRT is being considered, to confirm hypogonadism.
   • Core hormone tests: When symptoms suggest low testosterone, core testing includes total testosterone, free testosterone (measured by equilibrium dialysis or calculated), LH, and FSH. A DHT level is not needed for most hair-loss evaluations.
   • Thyroid check: TSH, free T3, and free T4 may be ordered when symptoms suggest thyroid disease, which can contribute to diffuse shedding.
   • Nutrient status: Ferritin (iron storage) and vitamin D may be checked when dietary history, fatigue, or diffuse shedding suggests deficiency.
2. Medical treatment: Treatments for DHT-related loss either reduce DHT or stimulate hair growth.
   • 5-alpha reductase inhibitors: Finasteride (Propecia) blocks the enzyme that converts testosterone to DHT. According to two 1-year randomized trials by Kaufman and colleagues in the Journal of the American Academy of Dermatology (1998), which enrolled 1,553 men aged 18 to 41, men taking finasteride 1 mg daily had about 107 more hairs than men on placebo in a 1-inch circle of balding crown at 1 year and 138 more at 2 years, while men on placebo continued to lose hair; adverse effects were minimal.^[1] Sexual side effects are reported in a small share of men and are worth discussing before starting.
   • Follicle stimulators: Minoxidil (Rogaine) was developed as a vasodilator. Its effect on hair does not work through hormones; it prolongs the anagen growth phase and increases follicle size.
   • Ketoconazole shampoo: This antifungal is sometimes added to treatment because it reduces scalp inflammation, but evidence that it regrows hair on its own is limited.
3. Monitoring: Hair growth is slow. It typically takes 3 to 6 months for shedding to stop and 6 to 12 months to see visible regrowth. For men on TRT, the prescriber may adjust the dose to avoid supraphysiological peaks, which could increase DHT exposure in susceptible men.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, with results interpreted by licensed providers. When appropriate, treatment is enclomiphene or an enclomiphene plus tadalafil tablet. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

Myth vs fact

Myth: Wearing hats suffocates hair and causes baldness.

Fact: Hats have no effect on the follicular blood supply or DHT levels. Traction alopecia is possible if a hat is painfully tight, but casual wear is harmless.

Myth: Bald men have “too much” testosterone.

Fact: Most balding men have normal testosterone levels. Their hair follicles are simply more sensitive to the DHT produced from that testosterone.

Myth: Masturbation causes hair loss by wasting protein or changing hormones.

Fact: There is no scientific evidence linking sexual activity or frequency to hair loss. Hormone fluctuations during sex are temporary and do not affect long-term follicular health.

Myth: If your father has hair, you are safe.

Fact: The primary genetics for baldness can be inherited from the mother’s side (the X chromosome), meaning looking at your maternal grandfather is often a better predictor, though genes from both parents contribute.

Bottom line

Testosterone does not directly cause hair loss; DHT acting on genetically sensitive follicles drives androgenetic alopecia. TRT may speed up shedding in predisposed men by increasing the testosterone available for DHT production, while finasteride and minoxidil can slow loss and support regrowth when used consistently under clinician guidance.

References

1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578-89. PMID: 9777765
2. Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg. 1998;24:1330-2. PMID: 9865198
3. HAMILTON JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53:708-28. PMID: 14819896
4. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28:755-63. PMID: 8496421
5. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923